Intermittent Fasting for Alzheimer's Disease
(TREAD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial investigates whether time-restricted eating, or intermittent fasting, can enhance cognitive function and metabolic health in individuals with mild cognitive impairment (MCI). Participants will fast for 16 hours and eat during an 8-hour window, five days a week, for three months. The trial aims to determine if this eating schedule is both feasible and beneficial for brain health. Ideal participants are adults with MCI who can use the internet and have a family member or friend to assist them. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research on dietary impacts on brain health.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What prior data suggests that time-restricted eating is safe for adults with mild cognitive impairment?
Previous studies have shown that time-restricted eating (TRE) is safe and well-tolerated by older adults. Participants fasted for 16 hours and ate during an 8-hour window, with most adapting easily to this routine. Research suggests that TRE might improve brain function and reduce inflammation linked to Alzheimer's disease. Significant harmful effects have not been reported, making TRE a promising and safe approach for improving health for most people.12345
Why are researchers excited about this trial?
Researchers are excited about using time-restricted eating for Alzheimer's disease because it offers a novel approach by focusing on when people eat rather than what they eat. Unlike traditional treatments that often rely on medications to manage symptoms, this method aims to potentially influence brain health through metabolic changes triggered by fasting. Time-restricted eating might improve cellular repair and brain function, offering a non-pharmaceutical option that could complement existing therapies. Additionally, this approach is relatively easy for participants to adopt and maintain, making it a practical lifestyle change that could support overall well-being.
What evidence suggests that time-restricted eating might be an effective treatment for Alzheimer's disease?
This trial will evaluate the effects of time-restricted eating, where participants fast for 16 hours and eat during an 8-hour period, on brain function in people with Alzheimer's disease. Research has shown that this eating pattern might improve skills like planning and decision-making. Other studies suggest it might also help the body align better with its natural daily rhythms, possibly easing disease symptoms. This method is generally safe and simple for older adults to try. While more research is needed, these early results are promising for improving brain health.34678
Who Is on the Research Team?
Yonas E Geda, MD, MSc
Principal Investigator
Barrow Neurological Institute, Alzheimer's Disease and Cognitive Disorders Division
Are You a Good Fit for This Trial?
This trial is for adults with mild cognitive impairment (MCI) who may have Alzheimer's. Participants will try a special eating schedule, fasting for 16 hours and only eating within an 8-hour window on weekdays for three months. The study aims to see if this can improve thinking skills and health markers in the blood.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants follow a 16/8 time-restricted eating regimen characterized by fasting for 16 hours and eating within an 8-hour window on 5 days per week for 3 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Time Restricted Eating
Find a Clinic Near You
Who Is Running the Clinical Trial?
St. Joseph's Hospital and Medical Center, Phoenix
Lead Sponsor
Arizona State University
Collaborator
Karlsruhe Institute of Technology
Collaborator
Mayo Clinic
Collaborator